Clinical Research Program

RSV Maternal Vaccine Study

RSV Maternal Vaccine Study

Sponsor: Pfizer

Study Description

This study will explore the safety of the study vaccine, Respiratory Syncytial Virus vaccine (RSV vaccine for short), and also see if giving the vaccine may help protect babies against RSV infection.  RSV is a virus that can cause respiratory illness in people of all ages. Babies and older adults are the most likely to get serious RSV illness, like wheezing or pneumonia, that leads to hospitalization. Currently, there is no specific treatment for RSV disease or any vaccine to protect against RSV infection in adults or babies. Vaccines stimulate the immune system to help make antibodies that help to fight against diseases; this is called an immune response. The main aim of this study is to assess the safety of the RSV vaccine. The RSV vaccine used in this study is experimental and has not been approved by the Food and Drug Administration (FDA) for the prevention of RSV disease. This study will also be measuring your immune response to the RSV vaccine, and how well the antibodies you make can help protect your baby from developing an RSV illness.  Pfizer’s RSV vaccine contains proteins found in the virus which will stimulate the body’s response to make antibodies which may protect against RSV disease. It does not contain any live virus.

Eligibility

You may qualify to participate if you:

  • Are a healthy pregnant woman, 18-49 years old
  • Are expecting a healthy baby
  • Are in your second of third trimester of pregnancy

Commitment:

This study has a commitment duration of up to 16 months with 9 visits.

Compensation:

If you qualify and decide to participate, you may receive up to $1,125.00 if all scheduled visits are completed. Additional compensation will be provided for any unscheduled visits

Contact Information:

To learn more or see if you qualify, call 804-661-5938